Investigators reanalyzed a public stable-isotope-resolved metabolomics dataset generated from patient-derived lung cancer tissue cultures to quantify how labeling patterns vary with treatment and tissue context. The study team worked from the originally deposited data and analysis code, aiming to recompute labeled pools and provide transparent estimates and uncertainty. The authors framed their work as an independent verification and assessment of statistical resolution in small, patient-derived experiments.
The reanalysis recalculated protein-normalized metabolite pools, isotopologue distributions, atom-percent excess values, and pathway-level summaries directly from the shared dataset. The source reported that tissues were traced with U-13C6-glucose or U-13C5,15N2-glutamine and exposed to vehicle or pembrolizumab in matched tumor/non-tumor slices from one patient, with an additional pembrolizumab × WGP β-glucan factorial experiment in tumor tissue from a second patient. The authors used log2-scale linear models to estimate effects, computed Hedges' g as an effect-size metric, and ran exact randomization tests that enumerated all assignments compatible with each experimental design. Benjamini–Hochberg q values were calculated within families of endpoints to address multiple comparisons.
In the UK131 tumor slices, the reanalysis indicated increases in several labeled intermediates and derived metrics reported by the source. Specifically, labeled non-oxidative pentose phosphate pathway intermediates increased by a reported fold change of 1.84 with a model P = 0.036; the exact randomization test for tumor-only assignments produced P = 0.10 and the exact interaction test P = 0.16, yielding q = 0.32 under the study's multiple-testing procedure. The reanalysis also found an increase in weighted isotopic scrambling (1.31-fold) for which the exact interaction P = 0.04 and q = 0.20, and a 1.66-fold increase in glutamine-derived glutathione diversion with exact interaction P = 0.09 and q = 0.22.
In the UK2035 tumor experiment, the combination treatment raised the labeled IMP/(ATP+GTP+UTP) ratio by 3.64-fold according to the model interaction term (model interaction P = 3.2 × 10^-4); the study team reported exact randomization P = 0.016 and q = 0.097 for that endpoint. The authors emphasized these directional findings matched the principal labeling patterns described in the source study.
The reanalysis contrasted standard model-based P values with exact randomization results that exhaustively enumerate compatible label assignments for the small-group designs. Data indicated that model-based P values can appear more favorable than permutation-based exact tests in these small patient-derived experiments. Crucially, the authors reported that no endpoint survived Benjamini–Hochberg correction at q < 0.05 when evaluated with the exact analyses. They therefore treated the observed fold changes and nominally significant model P values as estimates that require larger-sample confirmation.
The reanalysis reproduced the direction of the source study's principal labeling patterns but showed weaker statistical support under exact testing. The cohort-level signals—such as increased labeled non-oxidative pentose phosphate metabolites in one patient and a larger labeled IMP/(ATP+GTP+UTP) ratio in another—were reported with effect-size metrics and exact-test P values that often attenuated the inference compared with model-only results. The study team cautioned that these outcomes should be regarded as hypothesis-generating estimates rather than validated metabolic bottlenecks or definitive treatment effects.
The source dataset and analysis code are publicly available from Dryad; the reanalysis used those files. The source article reported that surgical patients were consented under an institutional protocol at the University of Kentucky and that appropriate ethical approvals and reporting guidelines were followed. The authors noted limitations inherent to the underlying experiment: small sample sizes, limited per-group replication, and the resulting constrained statistical resolution. The reanalysis did not report any new clinical recommendations. Remaining unanswered questions documented in the source include whether the observed labeling shifts would replicate in larger patient-derived cohorts, whether they are consistent across additional tumors and clinical contexts, and which of the nominally altered pathways represent robust, reproducible metabolic effects worthy of targeted follow-up.
Limitations recorded by the reanalysis team include the original experiment's small-group design and the fact that no endpoint met a strict multiple-testing threshold (q < 0.05) under exact permutation testing. The authors therefore recommend treating the results as a basis for larger, better-powered patient-derived metabolomics studies rather than as conclusive evidence of specific metabolic mechanisms.